Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Thoracic Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Thoracic Neoplasm

Cancer Family

Thoracic Neoplasm

CI-CAN-00000054Explore in graph →

Non-malignant2,891 active trials51 approved drugs626 evidence items

NCIt: C3406
MeSH: D013899

Overview
Statistics
Survival
Genomics51
Variants & evidence626
Drugs128
Trials12160
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (479)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 401–425 of 479 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations.
· J Thorac Oncol · 2011 · PMID 21716144 · validated civic_curation pubmed
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.
· Oncogene · 2008 · PMID 18408761 · validated civic_curation pubmed
CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.
· Cancer Res · 2017 · PMID 28490518 · validated civic_curation pubmed
Drug-sensitive FGFR3 mutations in lung adenocarcinoma.
· Ann Oncol · 2017 · PMID 27998968 · validated civic_curation pubmed
SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer.
· Nat Commun · 2019 · PMID 30718506 · validated civic_curation pubmed
CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.
· Cancer Cell · 2011 · PMID 21575866 · validated civic_curation pubmed
TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity.
· Oncogene · 2010 · PMID 19966866 · validated civic_curation pubmed

Showing 401–425 of 479 publications

← Previous
1
…
16
17
18
19
20
Next →

L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition.

· Int J Cancer · 2007 · PMID 17372901 · validated civic_curation pubmed

Oncogenic RIT1 mutations in lung adenocarcinoma.

· Oncogene · 2014 · PMID 24469055 · validated civic_curation pubmed

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

· Cancer Discov · 2013 · PMID 24065731 · validated civic_curation pubmed

Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer.

· Sci Transl Med · 2013 · PMID 23390248 · validated civic_curation pubmed

TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun.

· Oncotarget · 2016 · PMID 26745678 · validated civic_curation pubmed

MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer.

· Mol Cancer Ther · 2008 · PMID 18445659 · validated civic_curation pubmed

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

· Cancer Discov · 2014 · PMID 24893891 · validated civic_curation pubmed

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer.

· Nat Med · 2013 · PMID 24162815 · validated civic_curation pubmed

Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.

· Clin Cancer Res · 2015 · PMID 25351743 · validated civic_curation pubmed

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.

· Nature · 2012 · PMID 22425996 · validated civic_curation pubmed

Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.

· Proc Natl Acad Sci U S A · 2015 · PMID 26372962 · validated civic_curation pubmed

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.

· Proc Natl Acad Sci U S A · 2015 · PMID 25733882 · validated civic_curation pubmed

LKB1 gene inactivation does not sensitize non-small cell lung cancer cells to mTOR inhibitors in vitro.

· Acta Pharmacol Sin · 2015 · PMID 26027660 · validated civic_curation pubmed

Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors.

· Cancer Res · 2009 · PMID 19366796 · validated civic_curation pubmed

PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.

· Cancer Res · 2007 · PMID 18089823 · validated civic_curation pubmed

Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.

· Cancer Res · 2006 · PMID 16818618 · validated civic_curation pubmed

Amplification of EGFR Wild-Type Alleles in Non-Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors.

· Cancer Res · 2017 · PMID 28202511 · validated civic_curation pubmed

Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domain.

· Mol Cancer · 2007 · PMID 17877814 · validated civic_curation pubmed